Trovafloxacin mesylate - Generic Drug Details

What are the generic sources for trovafloxacin mesylate and what is the scope of patent protection?

Trovafloxacin mesylate is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for trovafloxacin mesylate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	44
DailyMed Link:	trovafloxacin mesylate at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for trovafloxacin mesylate

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for trovafloxacin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997		DISCN	No	No
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997		DISCN	No	No

Expired US Patents for trovafloxacin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997	5,763,454
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997	5,164,402
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997	5,164,402
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997	6,187,341
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997	5,763,454
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997	6,187,341

Trovafloxacin Mesylate Market Dynamics and Financial Trajectory

Last updated: September 3, 2026

Trovafloxacin mesylate was a broad-spectrum fluoroquinolone commercialized by Pfizer under the brand name Trovan after Pfizer acquired Warner-Lambert. The product received FDA approval in 1997 but was rapidly restricted because of serious, sometimes fatal hepatotoxicity. Its commercial trajectory shifted from an expected high-value anti-infective franchise to a regulatory liability, followed by withdrawal from routine U.S. sales. Product-specific revenue was not separately disclosed in Pfizer’s public financial statements, but the regulatory restrictions materially impaired the drug’s addressable market and eliminated its potential as a major long-term franchise.

What is trovafloxacin mesylate and how was it positioned commercially?

Trovafloxacin mesylate is the mesylate salt of trovafloxacin, a synthetic fluoroquinolone antibacterial. It was marketed in oral tablet form and as intravenous alatrofloxacin, the water-soluble prodrug used for injection.

The product was positioned as a broad-spectrum agent for serious bacterial infections, including respiratory, intra-abdominal, pelvic, skin and skin-structure, urinary tract and other hospital-associated infections. Its commercial differentiation came from activity against both Gram-negative and Gram-positive pathogens, including some organisms with resistance to older fluoroquinolones.

Product	Active ingredient	Route	Original commercial sponsor	U.S. regulatory status
Trovan	Trovafloxacin mesylate	Oral tablet	Warner-Lambert, later Pfizer	Approved in 1997; heavily restricted and subsequently withdrawn from routine U.S. marketing
Trovan IV	Alatrofloxacin, prodrug of trovafloxacin	Intravenous	Warner-Lambert, later Pfizer	Subject to the same hepatotoxicity restrictions
Generic trovafloxacin	Trovafloxacin mesylate	Oral	No meaningful commercial U.S. market identified	No active branded market

The drug’s early value proposition depended on use across multiple indications and the ability to substitute for several hospital antibiotics. That strategy failed when liver toxicity prevented broad outpatient and routine inpatient use.

When did trovafloxacin lose exclusivity and commercial viability?

Trovafloxacin’s commercial loss of exclusivity was less important than its earlier loss of regulatory usability.

Date	Event	Commercial effect
1997	FDA approved Trovan for multiple bacterial infections	Created a broad potential market
1998	Reports of severe hepatic injury increased	Prescribing restrictions and risk concerns emerged
1999	FDA issued a public health advisory and limited use to serious infections where alternatives were unavailable	Addressable market contracted sharply
2000	Pfizer completed its acquisition of Warner-Lambert	Trovan became part of Pfizer’s anti-infective portfolio
2001	Pfizer discontinued routine U.S. commercial distribution	Branded U.S. revenue effectively ended
After 2001	Product remained subject to limited or jurisdiction-specific availability rather than normal commercial use	No material U.S. growth opportunity remained

The original small-molecule patent estate would have reached the end of its ordinary U.S. term in the late 2000s or early 2010s, depending on the specific patent, filing date and patent-term adjustment. By that point, the product had already lost most commercial value because of the FDA restrictions.

What is the FDA regulatory status of Trovan?

Trovan is not a normal actively marketed U.S. antibiotic. FDA labeling identified serious and potentially fatal liver injury as the central safety risk. The agency restricted use to patients with serious infections for which alternative antibiotics were unavailable or unsuitable.[1,2]

The FDA label warned that trovafloxacin and alatrofloxacin had been associated with acute liver injury, including liver failure requiring transplantation and death. The risk was considered disproportionate to the product’s role in infections that could often be treated with safer agents.

The key regulatory consequences were:

• Removal of broad first-line and routine empiric use.
• Limitation to serious infections with inadequate alternatives.
• Reduced use in outpatient settings.
• Reduced formulary adoption by hospitals.
• Higher monitoring and pharmacovigilance costs.
• Loss of physician confidence and payer support.
• Eventual discontinuation of routine U.S. commercial distribution.

The safety action was commercially more damaging than ordinary patent expiry. A generic competitor could have entered after loss of exclusivity, but the restricted label left little economically attractive demand to capture.

What patents protected trovafloxacin mesylate?

Trovafloxacin was protected primarily by pre-approval small-molecule, composition-of-matter and pharmaceutical-use patents associated with Warner-Lambert’s quinolone research program. The relevant intellectual-property categories included:

Patent category	Protected subject matter	Commercial relevance
Composition of matter	Trovafloxacin chemical structure and related quinolone compounds	Core exclusivity
Salt and formulation	Mesylate salt, dosage forms and pharmaceutical compositions	Product development and stability
Method of use	Treatment of bacterial infections	Regulatory and commercial positioning
Manufacturing processes	Preparation of the active ingredient and intermediates	Potential process barriers

No active, commercially significant U.S. patent barrier is generally associated with trovafloxacin today. The relevant small-molecule patent terms have expired or become commercially immaterial. Historical patent numbers and Orange Book listings should be evaluated against the specific NDA and archived Orange Book editions because the product’s marketing status changed before ordinary patent expiry.

Did formulation patents protect oral or intravenous Trovan?

The oral and intravenous products used different pharmaceutical presentations. Trovafloxacin mesylate was used for oral administration, while alatrofloxacin was the intravenous prodrug. Any formulation, salt or prodrug claims would have provided narrower protection than the underlying active-compound claims.

Those claims did not solve the principal commercial problem. Formulation patents can delay direct substitution, but they cannot preserve a market when the FDA limits the product because of organ toxicity. The clinical safety profile applied across the product’s intended systemic use.

Were there Paragraph IV challenges to trovafloxacin?

No major, commercially consequential Paragraph IV litigation campaign is associated with trovafloxacin in the public record comparable to the challenges involving large-selling chronic medicines. The drug’s commercial collapse before a meaningful generic opportunity reduced the incentive for generic manufacturers to pursue an aggressive U.S. launch.

A Paragraph IV filing would have required a generic applicant to challenge listed patents or certify that the relevant patents were not infringed, invalid or unenforceable. The potential reward was limited because:

1. The FDA label restricted use to exceptional cases.
2. Hospitals had shifted away from the drug.
3. Physicians had safer alternatives.
4. Pfizer had already withdrawn routine marketing.
5. Product liability and pharmacovigilance exposure remained material.

The absence of a major Paragraph IV event should not be interpreted as strong residual patent protection. It primarily reflects weak commercial demand.

What litigation and settlement agreements affected Trovan?

Trovafloxacin generated significant legal exposure related to liver injury allegations and clinical-trial conduct. The most widely reported controversies involved the 1996 clinical trial in Nigeria during a meningitis outbreak, where families alleged inadequate consent procedures and harm to children treated with Trovan.

Pfizer ultimately resolved related Nigerian litigation through a settlement reported in 2009. The settlement ended a long-running dispute but did not restore the product’s commercial prospects.[3]

The litigation profile had two separate components:

Litigation area	Issue	Commercial implication
Product-liability claims	Hepatic injury, liver failure and death	Increased reserve, defense and reputational costs
Nigerian clinical-trial litigation	Consent, trial conduct and alleged injuries	Long-duration legal overhang and settlement expense
Patent litigation	No major public generic challenge identified	Limited effect on the product’s eventual decline

No publicly established settlement is known to have created a meaningful generic-delay period or extended the product’s practical market life.

How did trovafloxacin compare with competing antibiotics?

Trovafloxacin entered a crowded fluoroquinolone market. Its broad spectrum was commercially attractive, but competing drugs had stronger safety positions and established prescribing habits.

Drug	Company during major commercial period	Competitive position
Ciprofloxacin	Bayer and licensees	Strong Gram-negative coverage and established hospital use
Levofloxacin	Johnson & Johnson	Broad use in respiratory and hospital infections
Moxifloxacin	Bayer	Respiratory and broad-spectrum positioning
Gatifloxacin	Bristol-Myers Squibb	Broad-spectrum fluoroquinolone, later affected by dysglycemia concerns
Trovafloxacin	Warner-Lambert/Pfizer	Broad spectrum, undermined by severe hepatotoxicity

Trovafloxacin had potential advantages in complicated and mixed infections. Those advantages were insufficient against a safety signal involving irreversible liver injury. Physicians could substitute other fluoroquinolones, beta-lactam/beta-lactamase inhibitor combinations, carbapenems or other hospital antibiotics.

What was the financial trajectory of trovafloxacin?

Public filings do not provide a reliable standalone revenue series for Trovan. Pfizer and Warner-Lambert reported portfolio and segment results, rather than a complete product-level income statement for trovafloxacin. The financial trajectory can therefore be assessed through launch potential, market contraction and discontinuation events rather than exact annual sales.

Launch phase: high commercial expectations

The initial approval supported a broad label and a substantial hospital anti-infective opportunity. The product had the characteristics of a potential franchise drug:

• Multiple infection indications.
• Oral and intravenous formulations.
• Broad antibacterial coverage.
• Use in serious hospital infections.
• Potential substitution for several older agents.

Marketing investment, physician education and formulary placement were consistent with an expected high-value launch.

Restriction phase: rapid revenue compression

The FDA’s safety actions changed the economics. Once use was limited to cases with no suitable alternatives, the volume opportunity fell sharply. The restriction also made the product less attractive for:

• Routine empiric therapy.
• Step-down oral therapy.
• Outpatient prescriptions.
• Hospital protocols.
• Managed-care formularies.

The financial effects included lower unit volume, higher monitoring costs, greater legal reserves and reduced expected return on development and marketing expenditure.

Withdrawal phase: franchise value impairment

Pfizer’s discontinuation of routine U.S. distribution converted Trovan from a growth product into a residual or liability-managed asset. Any remaining demand was limited to exceptional clinical circumstances and jurisdictions where the product remained permitted.

The acquisition of Warner-Lambert by Pfizer in 2000 also affected the financial analysis. Trovan was one component of a much larger transaction, and Pfizer did not disclose the purchase price or subsequent impairment specifically attributable to Trovan. The product’s safety-related decline was therefore absorbed within broader corporate results rather than reported as a standalone financial collapse.[4]

What revenue exposure did Pfizer face?

The direct revenue exposure was the loss of expected sales from a recently approved broad-spectrum antibiotic. The larger exposure included:

• Sunk clinical-development and launch costs.
• Sales-force and manufacturing commitments.
• Legal defense and settlement payments.
• Product-liability reserves.
• Brand and corporate reputation costs.
• Lost opportunity to build follow-on anti-infective products around the platform.
• Lower value of related regulatory approvals and commercial infrastructure.

Trovan was not comparable to a blockbuster chronic medicine with predictable recurring prescriptions. Antibiotics generally have shorter treatment courses and lower cumulative patient revenue. The commercial case depended on high prescribing volume across many indications. FDA restrictions removed that volume before the product could mature.

Is there biosimilar or generic risk for trovafloxacin?

Biosimilar risk is zero because trovafloxacin is a small-molecule antibiotic, not a biologic. The relevant substitution risk is generic competition.

Generic risk is currently low in commercial terms because the U.S. market is not meaningfully active. If a manufacturer sought approval, it would face more than patent considerations:

• Limited demand under the restricted safety profile.
• Difficult hospital formulary positioning.
• Physician reluctance to use the drug.
• Safety-monitoring requirements.
• Product-liability exposure.
• Competition from established alternatives.
• Potential regulatory and manufacturing complexity for oral and injectable presentations.

A generic launch could be legally possible after patent expiry but commercially unattractive. The likely launch scenario would be a limited, institution-focused product rather than a broad outpatient brand competitor.

How strong is the current patent estate for trovafloxacin?

The current patent estate is commercially weak. Historical composition and related pharmaceutical patents may have delayed generic competition during the original product life, but they no longer create a meaningful barrier to market entry.

The more important barrier is market failure caused by safety. Patent strength would not materially improve the investment case unless a new formulation or targeted delivery system could reduce systemic exposure and demonstrate a materially improved liver-safety profile. No such revived commercial program is established in the cited public record.

What licensing or partnership deals involved trovafloxacin?

Trovafloxacin originated within Warner-Lambert’s pharmaceutical business and became part of Pfizer’s portfolio through Pfizer’s acquisition of Warner-Lambert. The transaction was a corporate acquisition rather than a later product-specific licensing deal designed to extend Trovan’s life.

No major post-withdrawal licensing transaction is publicly established as having commercialized trovafloxacin through a new indication, delivery system or regional relaunch.

What generic launch scenarios exist?

A new generic entrant would most likely choose one of three strategies:

1. Limited hospital supply for exceptional cases.
2. Regional marketing outside the United States, subject to local approval.
3. A reformulated product supported by new clinical evidence, which would require substantial investment and would face regulatory risk.

A broad U.S. generic launch is unlikely to produce significant revenue without a change in the safety profile, label or treatment guidelines.

Key Takeaways

• Trovafloxacin mesylate was approved by the FDA in 1997 and marketed as Trovan.
• Severe hepatotoxicity caused FDA restrictions beginning in the late 1990s.
• Pfizer discontinued routine U.S. commercial distribution in 2001.
• Product-specific revenue was not separately disclosed by Pfizer.
• The drug’s commercial decline preceded meaningful generic competition.
• Historical composition, formulation and use patents are no longer a significant current barrier.
• Biosimilar risk does not apply because trovafloxacin is a small molecule.
• Generic risk is legally more relevant than commercially relevant.
• Litigation included liver-injury claims and the Nigerian clinical-trial dispute, which was settled in 2009.
• The product’s principal barrier today is weak demand and safety liability, not patent protection.

FAQs

Was Trovan ever a blockbuster antibiotic?

No. Trovan had broad-label launch potential, but safety restrictions prevented it from developing into a durable blockbuster franchise.

Is trovafloxacin still approved by the FDA?

Trovafloxacin was FDA-approved, but routine U.S. commercial availability was discontinued after serious liver toxicity concerns. It should not be treated as an actively marketed U.S. antibiotic.

What company originally developed Trovan?

Warner-Lambert developed and marketed Trovan. Pfizer acquired Warner-Lambert in 2000 and inherited the product.

Can a generic manufacturer still sell trovafloxacin?

A manufacturer could pursue approval subject to current regulatory requirements, but the restricted safety profile, limited demand and liability exposure make a broad commercial launch unattractive.

Did the Nigerian Trovan trial cause Pfizer to withdraw the drug?

The principal driver of withdrawal was serious hepatotoxicity and the resulting FDA restrictions. The Nigerian trial produced separate litigation and settlement exposure.

References

1. U.S. Food and Drug Administration. (1999). Public health advisory: Trovan (trovafloxacin mesylate/alatrofloxacin mesylate).
2. U.S. Food and Drug Administration. (1998). Trovan prescribing information.
3. Reuters. (2009). Pfizer settles Trovan lawsuit in Nigeria.
4. Pfizer Inc. (2001). Annual report for the fiscal year ended December 31, 2000.